XPO1 and prostate carcinoma: One of the most common examples is the role of XPO1 inhibition leading to the accumulation of TP53 in the nucleus, an exciting finding of a possible mechanism explaining its anti-proliferative effects in leukemia, lymphoma, prostate cancer, melanoma, and hepatocellular carcinoma [26–28].